Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma

References

• Syed YY. Fluticasone furoate/vilanterol: a review of its use in patients with asthma. Drugs. 2015;75(4):407–418.
   PubMed Web of Science ®Google Scholar
• Matera MG, Capuano A, Cazzola M. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2015;9(1):5–12.
   PubMed Web of Science ®Google Scholar
• Banerji D, Mahler DA, Hanania NA. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. Expert Rev Respir Med. 2016 May 4;10:767–780.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183–192.
   PubMed Web of Science ®Google Scholar
• Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol. 2009;71:489–507.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118:3546–3556.
   PubMed Web of Science ®Google Scholar
• Barnes P. Biochemical basis of asthma therapy. J Biol Chem. 2011;286:38.
   Web of Science ®Google Scholar
• Montuschi P, Barnes PJ. New perspectives in pharmacological treatment of mild persistent asthma. Drug Discov Today. 2011;16(23–24):1084–1091.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol. 2010. 31. 120(2–3):76–85.
   PubMed Web of Science ®Google Scholar
• Partridge MR, van der Molen T, Myrseth S-E, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13.
   PubMedGoogle Scholar
• Chapman KR, Boulet LP, Rea RM, et al. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J. 2008;31:320–325.
   PubMed Web of Science ®Google Scholar
• Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8:54.
   PubMed Web of Science ®Google Scholar
• Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem. 2008;51(12):3349–3352.
   PubMed Web of Science ®Google Scholar
• Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L660–L667.
   PubMed Web of Science ®Google Scholar
• Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013;52:37–42.
   PubMed Web of Science ®Google Scholar
• Hughes S, Shardlow P, Hollis F, et al. Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos. 2008;36(11):2337–2344.
   PubMed Web of Science ®Google Scholar
• Jonsson G, Astrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CTP3A) enzymes in human liver. Drug Metab Dispos. 1995;23(1):37–42.
   Web of Science ®Google Scholar
• Allen A, Bal J, Cheesbrough A, et al. Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Brit J Clin Pharmacol. 2014;77(5):808–820.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Seckl JL. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax. 1997;52:476–482.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941–955
   Google Scholar
• Woodcock A, Bateman ED, Busse WW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomised, placebo-controlled trial. Respir Res. 2011;12:132.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011;12:160.
   PubMed Web of Science ®Google Scholar
• Medley H, Orozco S, Allen A. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Clin Ther. 2012;34(8):1683–1695.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012;67(1):35–41.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Bateman ED, Busse WW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol. 2012;109(5):353–358.
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bleecker ER, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Respir Med. 2014;108(1):41–49.
   PubMed Web of Science ®Google Scholar
• Assessment report: fluticasone furoate/vilanterol. European Medicine Agency; 2013 [cited 2016 Jan]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessmen=report/human/002673/WC500157635.pdf
   Google Scholar
• Van den Berge M, Luijk B, Bareille P, et al. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy. 2010;65(12):1531–1535.
   PubMed Web of Science ®Google Scholar
• Kempsford R, Bal J, Baines A, et al. The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma. Respir Med. 2016;112:18–24.
   PubMed Web of Science ®Google Scholar
• Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J. 2001;17(6):1083–1088.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012;106(5):642–650.
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, Lahdensuo A, Moilanen E, et al. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res. 2004;5:17.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res. 2004;5:17. DOI:10.1186/1465-9921-5-17
   PubMed Web of Science ®Google Scholar
• Busse WW, Bateman ED, O’Byrne PM, et al. Once-daily fluticasone furoate 50µg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Allergy. 2014;69(11):1522–1530.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Woodcock A, Bleecker ER, et al. Efficacy and safety of once-daily fluticasone furoate 50µg in adults with persistent asthma: a 12-week randomized trial. Respir Res. 2014;15:88. doi:10.1186/s12931-014-0088-z.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Lötvall J, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. BMC Pulm Med. 2014;14:113. doi:10.1186/1471-2466-14-113.
   PubMed Web of Science ®Google Scholar
• Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting β2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26:256–264.
   PubMed Web of Science ®Google Scholar
• Johnson E, Druey K. Heterotrimeric G protein signaling: role in asthma and allergic inflammation. J Allergy Clin Immunol. 2002;109(4):592–602.
   PubMed Web of Science ®Google Scholar
• Montuschi C. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015;58(10):4131–4164.
   PubMed Web of Science ®Google Scholar
• Slack R, Barrett VJ, Ford AJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344:218–230.
   PubMed Web of Science ®Google Scholar
• Slack R. Evidence for a non-β2-adrenoceptor binding site in human lung tissue for a subset of β2-adrenoceptor agonists. J Pharmacol. 2014;5:30–36.
   Google Scholar
• Malerba M, Radaeli A, Montuschi P, et al. Vilanterol trifenatate for the treatment of COPD. Expert Rev Respir Med. 2016;10(7):719–731.
   PubMed Web of Science ®Google Scholar
• Procopiou PA, Barrett VJ, Bevan NJ, et al. Synthesis and structure-activity relationships of long-acting ß2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53(11):4522–4530.
   PubMed Web of Science ®Google Scholar
• Harrell AW, Siederer SK, Bal J, et al. Metabolism and disposition of vilanterol, a long-acting β2-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013;41(1):89–100.
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bateman ED, Bleecker ER, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J. 2012;40(3):570–579.
   PubMed Web of Science ®Google Scholar
• Sterling R, Lim J, Frith L, et al. Efficacy and optimal dosing interval of the long-acting ß2 agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med. 2012;106(8):1110–1115.
   PubMed Web of Science ®Google Scholar
• Sears MR. Adverse effects of β-agonists. J Allergy Clin Immunol. 2002;110:S322–8.
   PubMedGoogle Scholar
• Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther. 2007;20:740–749.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Reynolds C, Pleskow W, et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily β2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther. 2011;49:153–61.
   PubMed Web of Science ®Google Scholar
• Burgess C, Ayson M, Rajasingham S, et al. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol. 1998;54:141–147.
   PubMed Web of Science ®Google Scholar
• Maconochie JG, Minton NA, Chilton JE, et al. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Br J Clin Pharmac. 1994;37:199–204.
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bateman ED, Busse WW, et al. Comparison of vilanterol, a novel long-acting β2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. J Negat Results Biomed. 2014;13(1):9. doi:10.1186/1477-5751-13-9.
   PubMedGoogle Scholar
• Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477–1495.
   PubMed Web of Science ®Google Scholar
• Panina-Bordignon P, Mazzeo D, Lucia PD, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest. 1997;100(6):1513–1519.
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Bhoi S. Comparing the efficacy and safety of two regimens of sequential systemic corticosteroids in the treatment of acute exacerbation of bronchial asthma. J Emerg Trauma Shock. 2010;3(3):231–237.
   PubMedGoogle Scholar
• Jaeschke R, O’Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and meta-analysis. Am J Respir Crit Care Med. 2008;178:1009–1016.
   PubMed Web of Science ®Google Scholar
• Barnes P. Severe asthma: advances in current management and future. J Allergy Clin Immunol. 2012;129:48–59.
   PubMed Web of Science ®Google Scholar
• Leukotrienes MP. Antileukotrienes and asthma. Mini Rev Med Chem. 2008;8(7):647–656.
   PubMed Web of Science ®Google Scholar
• Baraniuk J, Ali M, Brody D, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med. 1997;155:704–710.
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta-2 adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem. 1999;274:1005–1010.
   PubMed Web of Science ®Google Scholar
• Barnes P. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19:182–191.
   PubMed Web of Science ®Google Scholar
• Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest. 2005;127(4):1312–1326.
   PubMed Web of Science ®Google Scholar
• Gibson P, Powell H, Ducharme F. Differential effects of maintenance long-acting ß-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol. 2007;119:344–350.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Lotvall J, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomised trial. Chest. 2013;144(4):1222–1229.
   PubMed Web of Science ®Google Scholar
• Smith I, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther. 2003;16:79–95.
   PubMed Web of Science ®Google Scholar
• Newman S. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther. 2004;4(1):22–23.
   Web of Science ®Google Scholar
• Albertson TE, Richards JR, Zeki AA. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience. Ther Adv Respir Dis. 2016;10(1):43–56.
   PubMed Web of Science ®Google Scholar
• Tan LD, Chan AL, Albertson TE. New combination treatments in the management of asthma: focus on fluticasone/vilanterol. J Asthma Allergy. 2014;3(7):77–83.
   Google Scholar